Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The company reports a first-quarter adjusted loss of 24 cents per share, beating analyst ...

CHICAGO, May 06, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial ...

CHICAGO, May 05, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of ...

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...

Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. Analysts expect revenue of $248.1 ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical ...